FI94837C - Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina - Google Patents

Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina Download PDF

Info

Publication number: FI94837C
Authority: FI; Finland
Prior art keywords: water; monoester; solution; solid solution; pharmaceutically active
Prior art date: 1987-09-15

Application number

FI884192A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI94837B (fi

FI884192L (fi

FI884192A0 (fi

Inventor

Lorenz Hahn

Original Assignee

Sandoz Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-15

Filing date

1988-09-13

Publication date

1995-11-10

1988-09-13 Application filed by Sandoz Ag filed Critical Sandoz Ag

1988-09-13 Publication of FI884192A0 publication Critical patent/FI884192A0/fi

1989-03-16 Publication of FI884192L publication Critical patent/FI884192L/fi

1995-07-31 Publication of FI94837B publication Critical patent/FI94837B/fi

1995-11-10 Application granted granted Critical

1995-11-10 Publication of FI94837C publication Critical patent/FI94837C/fi

Links

150000001875 compounds Chemical class 0.000 title claims description 42
239000000126 substance Substances 0.000 title claims description 13
239000000969 carrier Substances 0.000 title description 16
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 title 1
239000006104 solid solution Substances 0.000 claims description 64
239000000243 solution Substances 0.000 claims description 62
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 36
239000002904 solvent Substances 0.000 claims description 24
235000014113 dietary fatty acids Nutrition 0.000 claims description 20
229930195729 fatty acid Natural products 0.000 claims description 20
239000000194 fatty acid Substances 0.000 claims description 20
108090000765 processed proteins & peptides Proteins 0.000 claims description 18
KGUHOFWIXKIURA-VQXBOQCVSA-N [(2r,3s,4s,5r,6r)-6-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl dodecanoate Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)CCCCCCCCCCC)O[C@@H]1O[C@@]1(CO)[C@@H](O)[C@H](O)[C@@H](CO)O1 KGUHOFWIXKIURA-VQXBOQCVSA-N 0.000 claims description 17
229940032085 sucrose monolaurate Drugs 0.000 claims description 17
102000004196 processed proteins & peptides Human genes 0.000 claims description 16
229920001184 polypeptide Polymers 0.000 claims description 15
MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 13
MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 13
238000000034 method Methods 0.000 claims description 13
MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 13
239000013543 active substance Substances 0.000 claims description 10
239000006193 liquid solution Substances 0.000 claims description 9
150000004665 fatty acids Chemical class 0.000 claims description 8
150000001720 carbohydrates Chemical class 0.000 claims description 7
229920006395 saturated elastomer Polymers 0.000 claims description 6
239000003795 chemical substances by application Substances 0.000 claims description 4
238000001816 cooling Methods 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 2
238000002844 melting Methods 0.000 claims description 2
230000008018 melting Effects 0.000 claims description 2
239000012736 aqueous medium Substances 0.000 claims 2
229960001265 ciclosporin Drugs 0.000 description 73
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 68
108010036949 Cyclosporine Proteins 0.000 description 67
229930182912 cyclosporin Natural products 0.000 description 58
229930105110 Cyclosporin A Natural products 0.000 description 35
239000000203 mixture Substances 0.000 description 29
-1 3-methoxy-4-hydroxycinnamic acid triterpene alcohol ester Chemical class 0.000 description 22
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
239000003125 aqueous solvent Substances 0.000 description 15
239000007864 aqueous solution Substances 0.000 description 13
150000002148 esters Chemical class 0.000 description 13
239000000546 pharmaceutical excipient Substances 0.000 description 13
238000002360 preparation method Methods 0.000 description 13
238000011282 treatment Methods 0.000 description 13
229930006000 Sucrose Natural products 0.000 description 12
239000005720 sucrose Substances 0.000 description 12
108010036941 Cyclosporins Proteins 0.000 description 11
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 10
238000001990 intravenous administration Methods 0.000 description 10
238000009472 formulation Methods 0.000 description 9
JTIGKVIOEQASGT-UHFFFAOYSA-N proquazone Chemical compound N=1C(=O)N(C(C)C)C2=CC(C)=CC=C2C=1C1=CC=CC=C1 JTIGKVIOEQASGT-UHFFFAOYSA-N 0.000 description 9
229960002466 proquazone Drugs 0.000 description 9
239000008137 solubility enhancer Substances 0.000 description 9
239000004480 active ingredient Substances 0.000 description 8
239000002253 acid Substances 0.000 description 7
239000002552 dosage form Substances 0.000 description 7
238000001802 infusion Methods 0.000 description 7
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 6
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
239000006185 dispersion Substances 0.000 description 6
238000001704 evaporation Methods 0.000 description 6
239000000047 product Substances 0.000 description 6
238000010790 dilution Methods 0.000 description 5
239000012895 dilution Substances 0.000 description 5
239000007788 liquid Substances 0.000 description 5
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 5
229920005862 polyol Polymers 0.000 description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
239000012141 concentrate Substances 0.000 description 4
POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
150000003077 polyols Chemical class 0.000 description 4
238000001556 precipitation Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
206010010741 Conjunctivitis Diseases 0.000 description 3
108010069514 Cyclic Peptides Proteins 0.000 description 3
102000001189 Cyclic Peptides Human genes 0.000 description 3
201000004681 Psoriasis Diseases 0.000 description 3
XZAGBDSOKNXTDT-UHFFFAOYSA-N Sucrose monopalmitate Chemical compound CCCCCCCCCCCCCCCC(O)=O.OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(CO)O1 XZAGBDSOKNXTDT-UHFFFAOYSA-N 0.000 description 3
239000000654 additive Substances 0.000 description 3
230000003110 anti-inflammatory effect Effects 0.000 description 3
230000002141 anti-parasite Effects 0.000 description 3
230000001363 autoimmune Effects 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
230000001506 immunosuppresive effect Effects 0.000 description 3
230000004968 inflammatory condition Effects 0.000 description 3
239000007791 liquid phase Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
239000008194 pharmaceutical composition Substances 0.000 description 3
229940124531 pharmaceutical excipient Drugs 0.000 description 3
239000012071 phase Substances 0.000 description 3
239000000843 powder Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
238000011160 research Methods 0.000 description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
GEUKOOCPPICVTB-SMOCYEBVSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s)-33-[(1r,2r)-1-hydroxy-2-methylhexyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32- Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O GEUKOOCPPICVTB-SMOCYEBVSA-N 0.000 description 2
208000023275 Autoimmune disease Diseases 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical group C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
239000005639 Lauric acid Substances 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
ZFFCNTZCHDDATQ-UWFDMBNGSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hexanoate Chemical compound CCCCCC(=O)O[C@@]1([C@]2(CO)[C@H]([C@H](O)[C@@H](CO)O2)O)O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O ZFFCNTZCHDDATQ-UWFDMBNGSA-N 0.000 description 2
150000001408 amides Chemical group 0.000 description 2
239000003708 ampul Substances 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
230000000845 anti-microbial effect Effects 0.000 description 2
239000003096 antiparasitic agent Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000004359 castor oil Substances 0.000 description 2
235000019438 castor oil Nutrition 0.000 description 2
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
108010040781 dihydrocyclosporin D Proteins 0.000 description 2
150000002016 disaccharides Chemical class 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000008020 evaporation Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
235000013305 food Nutrition 0.000 description 2
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 2
238000000227 grinding Methods 0.000 description 2
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 2
229940125721 immunosuppressive agent Drugs 0.000 description 2
239000003018 immunosuppressive agent Substances 0.000 description 2
238000011221 initial treatment Methods 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
238000010253 intravenous injection Methods 0.000 description 2
208000017169 kidney disease Diseases 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
229960002216 methylparaben Drugs 0.000 description 2
238000002156 mixing Methods 0.000 description 2
239000004570 mortar (masonry) Substances 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
230000001376 precipitating effect Effects 0.000 description 2
210000003491 skin Anatomy 0.000 description 2
238000003756 stirring Methods 0.000 description 2
239000000829 suppository Substances 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
150000004043 trisaccharides Chemical class 0.000 description 2
102000003390 tumor necrosis factor Human genes 0.000 description 2
JTOKYIBTLUQVQV-QRVTZXGZSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-30-[(1r)-1-hydroxyethyl]-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontan Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H]([C@@H](C)O)NC1=O JTOKYIBTLUQVQV-QRVTZXGZSA-N 0.000 description 1
ZNVBEWJRWHNZMK-SYOLRUPNSA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21,30-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,2 Chemical compound C\C=C\C[C@@H](C)[C@@H](O)[C@@H]1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C(=O)[C@H](C(C)C)NC1=O ZNVBEWJRWHNZMK-SYOLRUPNSA-N 0.000 description 1
ZMKGDQSIRSGUDJ-VSROPUKISA-N (3s,6s,9s,12r,15s,18s,21s,24s,30s,33s)-33-[(e,1r,2r)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-30-propyl-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,1 Chemical compound CCC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZMKGDQSIRSGUDJ-VSROPUKISA-N 0.000 description 1
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
QIZPVNNYFKFJAD-UHFFFAOYSA-N 1-chloro-2-prop-1-ynylbenzene Chemical compound CC#CC1=CC=CC=C1Cl QIZPVNNYFKFJAD-UHFFFAOYSA-N 0.000 description 1
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical class O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 1
208000032467 Aplastic anaemia Diseases 0.000 description 1
208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
206010008909 Chronic Hepatitis Diseases 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
JTOKYIBTLUQVQV-UHFFFAOYSA-N Cyclosporin C Natural products CC=CCC(C)C(O)C1N(C)C(=O)C(C(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(CC(C)C)N(C)C(=O)C(C)NC(=O)C(C)NC(=O)C(CC(C)C)N(C)C(=O)C(C(C)C)NC(=O)C(CC(C)C)N(C)C(=O)CN(C)C(=O)C(C(C)O)NC1=O JTOKYIBTLUQVQV-UHFFFAOYSA-N 0.000 description 1
QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical group CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
NTURVSFTOYPGON-UHFFFAOYSA-N Dihydroquinazoline Chemical compound C1=CC=C2C=NCNC2=C1 NTURVSFTOYPGON-UHFFFAOYSA-N 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
206010017533 Fungal infection Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
208000023661 Haematological disease Diseases 0.000 description 1
206010019755 Hepatitis chronic active Diseases 0.000 description 1
206010020751 Hypersensitivity Diseases 0.000 description 1
206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
241001465754 Metazoa Species 0.000 description 1
235000021360 Myristic acid Nutrition 0.000 description 1
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
206010029164 Nephrotic syndrome Diseases 0.000 description 1
239000005642 Oleic acid Substances 0.000 description 1
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
206010033078 Otitis media Diseases 0.000 description 1
235000021314 Palmitic acid Nutrition 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
208000012654 Primary biliary cholangitis Diseases 0.000 description 1
201000001263 Psoriatic Arthritis Diseases 0.000 description 1
208000036824 Psoriatic arthropathy Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
208000025747 Rheumatic disease Diseases 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000016807 X-linked intellectual disability-macrocephaly-macroorchidism syndrome Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000000735 allogeneic effect Effects 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
229960004543 anhydrous citric acid Drugs 0.000 description 1
230000000692 anti-sense effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940125687 antiparasitic agent Drugs 0.000 description 1
201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 description 1
150000001545 azulenes Chemical class 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
150000001555 benzenes Chemical class 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
235000013361 beverage Nutrition 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000000747 cardiac effect Effects 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
210000004087 cornea Anatomy 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000006071 cream Substances 0.000 description 1
125000004122 cyclic group Chemical group 0.000 description 1
108010019248 cyclosporin C Proteins 0.000 description 1
108010019594 cyclosporin D Proteins 0.000 description 1
108010019249 cyclosporin G Proteins 0.000 description 1
238000000354 decomposition reaction Methods 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
201000001981 dermatomyositis Diseases 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000003814 drug Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000007938 effervescent tablet Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
239000003925 fat Substances 0.000 description 1
125000005313 fatty acid group Chemical group 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
208000024386 fungal infectious disease Diseases 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
239000000499 gel Substances 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
230000002949 hemolytic effect Effects 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003165 hydrotropic effect Effects 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
230000009610 hypersensitivity Effects 0.000 description 1
208000016036 idiopathic nephrotic syndrome Diseases 0.000 description 1
239000012535 impurity Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
229940125396 insulin Drugs 0.000 description 1
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
229960004958 ketotifen Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000012633 leachable Substances 0.000 description 1
230000003902 lesion Effects 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
229940083747 low-ceiling diuretics xanthine derivative Drugs 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
206010025135 lupus erythematosus Diseases 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
238000011418 maintenance treatment Methods 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
239000000463 material Substances 0.000 description 1
239000000155 melt Substances 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
206010028417 myasthenia gravis Diseases 0.000 description 1
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
229940049964 oleate Drugs 0.000 description 1
230000010494 opalescence Effects 0.000 description 1
239000006186 oral dosage form Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
201000008482 osteoarthritis Diseases 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
239000008188 pellet Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
239000002504 physiological saline solution Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000728 polyester Polymers 0.000 description 1
239000008389 polyethoxylated castor oil Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
102000007739 porin activity proteins Human genes 0.000 description 1
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
229960004618 prednisone Drugs 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
206010039073 rheumatoid arthritis Diseases 0.000 description 1
201000004409 schistosomiasis Diseases 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
230000035939 shock Effects 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
229950004959 sorbitan oleate Drugs 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010025 steaming Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
229940035023 sucrose monostearate Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000010189 synthetic method Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
230000001256 tonic effect Effects 0.000 description 1
239000006208 topical dosage form Substances 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
238000005199 ultracentrifugation Methods 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

FI884192A 1987-09-15 1988-09-13 Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina FI94837C (fi)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
DE3730909		1987-09-15
DE3730909		1987-09-15
DE3802355		1988-01-27
DE3802355		1988-01-27

Publications (4)

Publication Number	Publication Date
FI884192A0 FI884192A0 (fi)	1988-09-13
FI884192L FI884192L (fi)	1989-03-16
FI94837B FI94837B (fi)	1995-07-31
FI94837C true FI94837C (fi)	1995-11-10

Family

ID=25859774

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
FI884192A FI94837C (fi)	1987-09-15	1988-09-13	Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina

Country Status (24)

Country	Link
JP (1)	JP3090666B2 (da)
KR (1)	KR0131084B1 (da)
AT (1)	AT395819B (da)
AU (1)	AU628787B2 (da)
BE (1)	BE1001204A5 (da)
CA (1)	CA1338775C (da)
CH (1)	CH683672A5 (da)
DK (1)	DK175132B1 (da)
ES (1)	ES2012118A6 (da)
FI (1)	FI94837C (da)
FR (1)	FR2620336B1 (da)
GB (1)	GB2209671B (da)
GR (1)	GR1002243B (da)
HU (1)	HU205010B (da)
IE (1)	IE61195B1 (da)
IL (1)	IL87746A (da)
IT (1)	IT1224886B (da)
LU (1)	LU87335A1 (da)
MY (1)	MY103769A (da)
NL (1)	NL195094C (da)
NO (1)	NO179434C (da)
NZ (1)	NZ226163A (da)
PT (1)	PT88492B (da)
SE (1)	SE503279C2 (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6007840A (en) *	1988-09-16	1999-12-28	Novartis Ag	Pharmaceutical compositions comprising cyclosporins
KR0148748B1 (ko) *	1988-09-16	1998-08-17	장 크라메르, 한스 루돌프 하우스	사이클로스포린을 함유하는 약학조성물
GR1000466B (el) *	1989-01-28	1992-07-30	Sandoz Ag	Μεθοδος παρασκευης νεων φαρμακευτικων μορφων κυκλοσπορινης.
BE1003009A5 (fr) *	1989-02-09	1991-10-22	Sandoz Sa	Nouvelles compositions pharmaceutiques a base de cyclosporines.
GB8916901D0 (en)	1989-07-24	1989-09-06	Sandoz Ltd	Improvements in or relating to organic compounds
US6262022B1 (en)	1992-06-25	2001-07-17	Novartis Ag	Pharmaceutical compositions containing cyclosporin as the active agent
SG45449A1 (en)	1992-05-13	1998-01-16	Sandoz Ltd	Ophthalmic compositions
DK0589843T3 (da)	1992-09-25	2002-04-02	Novartis Ag	Cyclosporinholdige farmaceutiske præparater
ES2308955T5 (es) *	1993-09-28	2012-04-03	R.P. Scherer Gmbh	Fabricación de cápsulas de gelatina blanda
ES2177652T3 (es)	1994-11-03	2002-12-16	Novartis Ag	Nuevas formas de preparacion de ciclosporina para la aplicacion oral con composicion simple y alta biodisponibilidad, y procedimiento para su obtencion.
US5766629A (en) *	1995-08-25	1998-06-16	Sangstat Medical Corporation	Oral cyclosporin formulations
US5827822A (en) *	1996-03-25	1998-10-27	Sangstat Medical Corporation	Cyclosporin a formulations as nanoparticles
US5962019A (en) *	1995-08-25	1999-10-05	Sangstat Medical Corporation	Oral cyclosporin formulations
US5834017A (en) *	1995-08-25	1998-11-10	Sangstat Medical Corporation	Oral cyclopsporin formulations
DE19544507B4 (de)	1995-11-29	2007-11-15	Novartis Ag	Cyclosporin enthaltende Präparate
TW414696B (en) *	1996-07-01	2000-12-11	Mitsubishi Kagaku Foods Kk	Anti-bacteria agent
KR20050084502A (ko)	1997-01-30	2005-08-26	노파르티스 아게	오일을 함유하지 않은 사이클로스포린 ａ 함유 제약 조성물
GB2326337A (en) *	1997-06-20	1998-12-23	Phares Pharma Holland	Homogeneous lipid compositions for drug delivery
US7732404B2 (en)	1999-12-30	2010-06-08	Dexcel Ltd	Pro-nanodispersion for the delivery of cyclosporin
WO2005037252A1 (en) *	2003-10-14	2005-04-28	Wockhardt Limited	Sterile gelling agents
JP5422871B2 (ja) *	2006-10-24	2014-02-19	不二製油株式会社	イソフラボン類組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL284933A (da) *	1961-10-31
GB1134878A (en) *	1966-05-12	1968-11-27	Suga Kazuo	Improvements in and relating to oryzanol solutions and compositions
FR5986M (da) *	1966-11-22	1968-06-21
BE787842A (fr) *	1971-08-25	1972-12-18	Sumito Chemical Cy Ltd	Procede de preparation d'une suspension aqueuse de cristaux stables du type non beta d'esters d'acides gras superieurs du chloramphenicol
JPS53107408A (en) *	1977-02-28	1978-09-19	Yamanouchi Pharmaceut Co Ltd	Micellar preparation for rectal infusion
SE445174B (sv) *	1978-03-07	1986-06-09	Sandoz Ag	Farmaceutisk komposition innehallande en cyklosporin och en berarsubstans
JPS57128634A (en) *	1981-02-03	1982-08-10	Eisai Co Ltd	Elastase-containing compound increasing absorption
EP0179583A1 (en) *	1984-10-04	1986-04-30	Merck & Co. Inc.	A system for enhancing the water dissolution rate and solubility of poorly soluble drugs
JPS61280435A (ja) *	1985-04-04	1986-12-11	Kanji Takada	サイクロスポリン類のリンパ指向性製剤

1988
- 1988-09-01 HU HU884518A patent/HU205010B/hu unknown
- 1988-09-12 BE BE8801044A patent/BE1001204A5/fr not_active IP Right Cessation
- 1988-09-12 LU LU87335A patent/LU87335A1/xx unknown
- 1988-09-12 FR FR888811953A patent/FR2620336B1/fr not_active Expired - Lifetime
- 1988-09-12 CH CH3398/88A patent/CH683672A5/de not_active IP Right Cessation
- 1988-09-13 NO NO884052A patent/NO179434C/no not_active IP Right Cessation
- 1988-09-13 CA CA000577214A patent/CA1338775C/en not_active Expired - Lifetime
- 1988-09-13 FI FI884192A patent/FI94837C/fi not_active IP Right Cessation
- 1988-09-13 IE IE277288A patent/IE61195B1/en not_active IP Right Cessation
- 1988-09-13 SE SE8803221A patent/SE503279C2/sv not_active IP Right Cessation
- 1988-09-13 NZ NZ226163A patent/NZ226163A/xx unknown
- 1988-09-13 GB GB8821443A patent/GB2209671B/en not_active Expired - Lifetime
- 1988-09-13 AU AU22172/88A patent/AU628787B2/en not_active Expired
- 1988-09-13 PT PT88492A patent/PT88492B/pt not_active IP Right Cessation
- 1988-09-14 IT IT8848349A patent/IT1224886B/it active
- 1988-09-14 KR KR1019880011874A patent/KR0131084B1/ko not_active Expired - Lifetime
- 1988-09-14 JP JP63231396A patent/JP3090666B2/ja not_active Expired - Lifetime
- 1988-09-14 IL IL87746A patent/IL87746A/xx active Protection Beyond IP Right Term
- 1988-09-14 DK DK198805111A patent/DK175132B1/da not_active IP Right Cessation
- 1988-09-14 MY MYPI88001027A patent/MY103769A/en unknown
- 1988-09-14 AT AT0224988A patent/AT395819B/de not_active IP Right Cessation
- 1988-09-14 GR GR880100602A patent/GR1002243B/el not_active IP Right Cessation
- 1988-09-15 NL NL8802275A patent/NL195094C/nl not_active IP Right Cessation
- 1988-09-15 ES ES8802831A patent/ES2012118A6/es not_active Expired - Lifetime

Also Published As

Publication number	Publication date
KR890004694A (ko)	1989-05-09
IE882772L (en)	1989-03-15
GR880100602A (el)	1989-06-22
IL87746A (en)	1992-07-15
DK511188D0 (da)	1988-09-14
ES2012118A6 (es)	1990-03-01
SE503279C2 (sv)	1996-05-13
ATA224988A (de)	1992-08-15
IE61195B1 (en)	1994-10-19
DK175132B1 (da)	2004-06-14
IT1224886B (it)	1990-10-24
BE1001204A5 (fr)	1989-08-16
DK511188A (da)	1989-03-16
JPH01151526A (ja)	1989-06-14
FI94837B (fi)	1995-07-31
GB2209671B (en)	1991-11-13
FI884192L (fi)	1989-03-16
AU628787B2 (en)	1992-09-24
LU87335A1 (fr)	1989-04-06
GB2209671A (en)	1989-05-24
NL8802275A (nl)	1989-04-03
IT8848349A0 (it)	1988-09-14
IL87746A0 (en)	1989-02-28
MY103769A (en)	1993-09-30
HUT49494A (en)	1989-10-30
FR2620336B1 (fr)	1991-10-25
KR0131084B1 (ko)	1998-04-17
CA1338775C (en)	1996-12-10
GB8821443D0 (en)	1988-10-12
NO179434C (no)	1996-10-09
PT88492A (pt)	1988-10-01
NO884052L (no)	1989-03-16
NO884052D0 (no)	1988-09-13
AT395819B (de)	1993-03-25
SE8803221L (sv)	1989-03-16
FI884192A0 (fi)	1988-09-13
HU205010B (en)	1992-03-30
NZ226163A (en)	1991-08-27
CH683672A5 (de)	1994-04-29
JP3090666B2 (ja)	2000-09-25
NL195094C (nl)	2003-12-17
SE8803221D0 (sv)	1988-09-13
GR1002243B (en)	1996-04-22
FR2620336A1 (fr)	1989-03-17
AU2217288A (en)	1989-04-27
NO179434B (no)	1996-07-01
PT88492B (pt)	1993-03-31

Legal Events

Date	Code	Title	Description
1995-07-03	BB	Publication of examined application
1997-08-27	PC	Transfer of assignment of patent	Owner name: NOVARTIS AG
2004-08-31	FG	Patent granted	Owner name: NOVARTIS AG
2008-10-23	MA	Patent expired

Publication	Publication Date	Title
FI94837B (fi)	1995-07-31	Vesiliukoisia monoestereitä käytettäväksi farmakologisesti aktiivisten yhdisteiden kantajana ja farmaseuttisten apuaineiden liukoisuutta lisäävinä aineina
DE69635720T2 (de)	2006-08-10	Pharmazeutische Zusammensetzungen von Cyclosporine mit einer Polyethoxylierten hydroxy-fettsäure
JP4073503B2 (ja)	2008-04-09	サイクロスポリンを含有する液体製剤とその調製方法
US5543393A (en)	1996-08-06	Cyclosporin containing powder composition
EP0650721B1 (en)	2000-09-13	Cyclosporin soft capsule
KR0137674B1 (ko)	1998-05-15	정맥주사용 약학적 조성물 및 이를 제조하는 방법
KR100471680B1 (ko)	2007-04-25	사이클로스포린제제
FI89065C (fi)	1993-09-30	Foerfarande foer framstaellning av en ny siklosporin kristallform
KR980008239A (ko)	1998-04-30	사이클로스포린-함유 약학적 조성물
BG62955B1 (bg)	2000-12-29	Лекарствени форми на циклоспорин за орално прилагане с висока биоактивност и метод за получаванетоим
JP2003507343A (ja)	2003-02-25	経口及び局所投与用の医薬組成物
EP1151755B1 (en)	2005-03-16	Pharmaceutical compositions comprising cyclosporin as active ingredient
KR100308779B1 (ko)	2001-11-15	사이클로스포린을함유한신규조성물
WO2010141068A1 (en)	2010-12-09	Opthalmic compositions of cyclosporin
DE3830494B4 (de)	2006-05-18	Wasserlösliche Monoester als Solubilisatoren für pharmakologische Wirkstoffe und pharmazeutische Hilfsstoffe
AU3043400A (en)	2000-07-31	Cyclosporin solution
KR0173349B1 (ko)	1999-02-01	사이클로스포린-함유 고체 분산체 조성물
SK123299A3 (en)	2000-02-14	Pharmaceutical compositions containing cyclosporin
KR20220124891A (ko)	2022-09-14	나파모스타트 또는 이의 염을 포함하는 에멀젼을 포함하는 약제학적 제제 및 이의 제조 방법
HK1010830B (en)	2004-10-29	Pharmaceutical compositions of cyclosporine with a polyethoxylated saturated hydroxy-fatty acid